Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 11/20 | 0.49 |
| ▸ | PREP | P48147 | 10/20 | 0.49 |
| ▸ | DPP4 | P27487 | 13/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.41 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27260568 | 1.00 | FAP (0.49) | FAPPREPDPP4DPP8DPP9 | |
| SCHEMBL25891871 | 1.00 | FAP (0.49) | FAPPREPDPP4DPP8DPP9 | |
| SCHEMBL25894962 | 1.00 | FAP (0.49) | FAPPREPDPP4DPP8DPP9 | |
| SCHEMBL27261585 | 1.00 | FAP (0.49) | FAPPREPDPP4DPP8DPP9 | |
| SCHEMBL25895023 | 1.00 | FAP (0.49) | FAPPREPDPP4DPP8DPP9 | |
| SCHEMBL25894986 | 1.00 | FAP (0.49) | FAPPREPDPP4DPP8DPP9 | |
| SCHEMBL25892262 | 0.99 | FAP (0.50) | FAPPREPDPP4DPP8DPP9 | |
| SCHEMBL25891862 | 0.99 | FAP (0.50) | FAPPREPDPP4DPP8DPP9 | |
| SCHEMBL27261389 | 0.96 | FAP (0.47) | FAPPREPDPP4DPP8DPP9 | |
| SCHEMBL25895232 | 0.93 | FAP (0.47) | FAPPREPDPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330275-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2023-10-19 | — | — | US | disclosed |
| US-11707539-B2 | FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330275-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | FAP, APC, FIBP | FAP 1/4885PREP 543/4885DPP4 147/4885 |
| US-11707539-B2 | FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto | FAP, APC, FIBP | FAP 1/4885PREP 543/4885DPP4 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.